An Update on the Management of Acute High-Risk Pulmonary Embolism

J Clin Med. 2022 Aug 17;11(16):4807. doi: 10.3390/jcm11164807.

Abstract

Hemodynamic instability and right ventricular (RV) dysfunction are the key determinants of short-term prognosis in patients with acute pulmonary embolism (PE). High-risk PE encompasses a wide spectrum of clinical situations from sustained hypotension to cardiac arrest. Early recognition and treatment tailored to each individual are crucial. Systemic fibrinolysis is the first-line pulmonary reperfusion therapy to rapidly reverse RV overload and hemodynamic collapse, at the cost of a significant rate of bleeding. Catheter-directed pharmacological and mechanical techniques ensure swift recovery of echocardiographic parameters and may possess a better safety profile than systemic thrombolysis. Further clinical studies are mandatory to clarify which pulmonary reperfusion strategy may improve early clinical outcomes and fill existing gaps in the evidence.

Keywords: catheter-based therapy; high-risk pulmonary embolism; multidisciplinary care team; surgical embolectomy; systemic thrombolysis.

Publication types

  • Review

Grants and funding

This research received no external funding.